<DOC>
	<DOCNO>NCT01490788</DOCNO>
	<brief_summary>Very low dose ( VLD ) cyclobenzaprine bedtime show promise treatment fibromyalgia , chemistry cyclobenzaprine require new formulation technology bedtime use . The present trial design assess safety tolerability TNX-102 2.4 mg ( new formulation cyclobenzaprine design result increase dosage precision decrease potential morning grogginess ) compare bio-availability TNX-102 2.4 mg cyclobenzaprine 5 mg tablet fast fed condition .</brief_summary>
	<brief_title>Comparative Bioavailability TNX-102 Cyclobenzaprine Effect Food Pharmacokinetics TNX-102 Healthy Adults</brief_title>
	<detailed_description>Very low dose ( VLD ) cyclobenzaprine bedtime show promise treatment fibromyalgia , chemistry cyclobenzaprine require new formulation technology bedtime use . Employing proprietary mixture approve lipid cyclobenzaprine , TNX-102 , design provide predictable absorption cyclobenzaprine result increase dosage precision decrease potential morning grogginess . As first step development TNX-102 treatment fibromyalgia , present single-center , randomize , open-label , single-dose , three-way-crossover trial design assess safety tolerability TNX-102 2.4 mg ( dose base result previous Phase 2a , proof-of-concept study - VPI-CY-0001.1 ) compare rate extent absorption TNX-102 2.4 mg cyclobenzaprine 5 mg tablet fast fed condition .</detailed_description>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<criteria>Healthy adult Male female Nonsmoker 1855 year old BMI &gt; 18.5 &lt; 30.0 With medically acceptable form contraception ( female ) . Any clinically significant abnormality include ECG abnormality vital sign abnormality ( systolic blood pressure &lt; 90 &gt; 140 mmHg , diastolic blood pressure low &lt; 50 &gt; 90 mmHg , heart rate &lt; 50 &gt; 100 BPM ) Any abnormal laboratory test ( include positivity Hep B , Hep C , HIV , Hemoglobin &lt; 128 g/L ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) ) History alcohol drug abuse dependence within 1 year and/or positive drug , cotinine , alcohol test Use drug ( within 30 day ) , supplement , food ( within 14 day ) know induce inhibit hepatic drug metabolism prior study medication Positive pregnancy test , breastfeed lactate Use medication hormonal contraceptive topical product , include OTC , natural health product , MAO inhibitor Participation investigational study within 30 day prior dose Donation plasma ( within 7 day ) , donation loss blood 50499 mL ( within30 day ) , &gt; 499 mL ( within 56 day ) prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>